Results

1–10 of 12 results for real world

12-Month Real-World Clinical and Anatomic Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2024
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian DME Patients in a Real-World Setting: The PRECISE Study
Michel R Giunta, MD
On Demand Cases, Courses, and Papers
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients
Franco M. Recchia, MD
Annual Meeting Talks
2021
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Updates from the Field
2022
Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs
Michael A. Singer, MD
Annual Meeting Talks
2020
Low rates of endophthalmitis with intravitreal aflibercept in real world Canadian practice - data from the large prospective study PEGASUS.
Michael Peter Fielden, MD, FRCS(C)
On Demand Cases, Courses, and Papers
2019
Real World Patient and Clinical Characteristics in Treatment Naive Neovascular Age-Related Macular Degeneration
Matthew P. Ohr, MD
On Demand Cases, Courses, and Papers
2019
“Real World” U.S. Outcomes of Anti-VEGF Therapy in Neovascular AMD: Risk of Vision Loss is Greatest in Patients with Better Baseline Visual Acuity
Thomas A. Ciulla, MD, MBA, FASRS
Annual Meeting Talks
2016